Last reviewed · How we verify
Iron oxide nanoparticles
Iron oxide nanoparticles is a Small molecule drug developed by NanoEcho AB. It is currently in Phase 2 development. Also known as: contrast agent, Contrast agent.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Iron oxide nanoparticles |
|---|---|
| Also known as | contrast agent, Contrast agent |
| Sponsor | NanoEcho AB |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging (PHASE1)
- Ferumoxytol-enhanced Magnetic Resonance Venography in Patients With Venous Diseases (PHASE2)
- Lymph Node Identification Using Magtrace and Magseed Before Chemotherapy
- The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. (NA)
- A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries
- Virtual Histology of the Bladder Wall for Bladder Cancer Staging (EARLY_PHASE1)
- ImmunoMRI for Assessment of Tumor-associated Macrophages (EARLY_PHASE1)
- Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iron oxide nanoparticles CI brief — competitive landscape report
- Iron oxide nanoparticles updates RSS · CI watch RSS
- NanoEcho AB portfolio CI
Frequently asked questions about Iron oxide nanoparticles
What is Iron oxide nanoparticles?
Who makes Iron oxide nanoparticles?
Is Iron oxide nanoparticles also known as anything else?
What development phase is Iron oxide nanoparticles in?
Related
- Manufacturer: NanoEcho AB — full pipeline
- Also known as: contrast agent, Contrast agent
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing